N-tert.-Butyl-phenylalanin | 92196-70-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-tert.-Butyl-phenylalanin
• 英文别名: 2-(Tert-butylamino)-3-phenylpropanoic acid
• CAS: 92196-70-8
• 化学式: C₁₃H₁₉NO₂
• 分子量: 221.299
• InChiKey: XJLBBYWDCSBIAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] METHODS FOR POST-FABRICATION FUNCTIONALIZATION OF POLY(ESTER UREAS)<br/>[FR] PROCÉDÉS POUR LA FONCTIONNALISATION DE POLY(ESTER-URÉES) APRÈS FABRICATION
  申请人：BECKER MATTHEW

  公开号：WO2015048728A1

  公开（公告）日：2015-04-02

  Amino acid-based poly(ester urea)s (PEU) are emerging as a class of polymers that have shown promise in regenerative medicine applications. Embodiments of the invention relate to the synthesis of PEUs carrying pendent "clickable" groups on modified tyrosine amino acids. The pendent species include alkyne, azide, alkene, tyrosine-phenol, and ketone groups. PEUs with Mw exceeding 100k Da were obtained via interfacial polycondensation methods and the concentration of pendent groups was varied by copolymerization. The incorporation of derivatizable functionalities is demonstrated using 1H NMR and UV-Vis spectroscopy methods. Electrospinning was used to fabricate PEU nanofibers with a diameters ranging from 350 nm to 500 nm. The nanofiber matricies possess mechanical strengths suitable for tissue engineering (Young's modulus: 30045 MPa; tensile stress: 8.51.2 MPa). A series of bioactive peptides and fluorescent molecules were conjugated to the surface of the nanofibers following electrospinning using bio-orthogonal reactions in aqueous media.

  基于氨基酸的聚（酯脲）（PEU）作为一类聚合物正在成为再生医学应用中显示出潜力的材料。发明的实施例涉及合成携带修饰酪氨酸氨基酸上“可点击”基团的PEU。这些基团包括炔基、叠氮基、烯烃、酪氨酸酚和酮基团。通过界面缩聚方法获得了分子量超过100k Da的PEU，并通过共聚合改变基团的浓度。使用1H核磁共振和紫外-可见光谱方法证明了可衍生功能的结合。电纺技术用于制备直径在350纳米至500纳米范围内的PEU纳米纤维。这些纳米纤维基质具有适用于组织工程的机械强度（杨氏模量：30045 MPa；拉伸应力：8.51.2 MPa）。在电纺后，一系列生物活性肽和荧光分子通过生物正交反应结合到纳米纤维表面。
• Antimicrobial compounds and formulations
  申请人：——

  公开号：US20030195144A1

  公开（公告）日：2003-10-16

  The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipoophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.

  本发明涉及使用分子制造药物，该分子包括长度为2至35个非氢原子的骨架，至少连接有两个笨重和亲脂性基团，并且具有至少一个阳离子多于阴离子的基团，用作破坏微生物细胞膜的药物，并且涉及使用包括长度为2至35个非氢原子的骨架的分子，该分子共价连接有一个超级笨重和亲脂性基团，包括至少9个非氢原子，并且具有至少两个阳离子多于阴离子的基团，作为膜作用抗微生物药物的用途，以及涉及此类分子的治疗方法，特别是包括肽衍生物和肽类似物的肽。
• INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE
  申请人：Farmer Luc J.

  公开号：US20090022688A1

  公开（公告）日：2009-01-22

  The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt, or mixtures thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.

  本发明涉及公式I的化合物：或其药学上可接受的盐或混合物，其抑制丝氨酸蛋白酶活性，特别是丝氨酸蛋白酶NS3-NS4A的活性。因此，它们通过干扰丙型肝炎病毒的生命周期而起作用，并可用作抗病毒剂。本发明还涉及包含所述化合物的药学上可接受的组合物，无论是用于体外使用还是用于治疗患有HCV感染的患者的给药，以及制备这些化合物的过程。本发明还涉及通过给予本发明的化合物制成的药物组合物来治疗患有HCV感染的患者的方法。
• Antimicrobial Compounds and Formulations
  申请人：Svendsen John Sigurd

  公开号：US20120108520A1

  公开（公告）日：2012-05-03

  The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.

  本发明涉及使用一种分子，其包含长度为2至35个非氢原子的骨架，并且至少连接有两个笨重和亲脂性基团，并且具有至少一个阳离子大于阴离子的基团，在制造破坏微生物细胞膜的药物方面使用该分子。另外，本发明还涉及使用一种分子作为膜作用抗微生物剂，该分子包括长度为2至35个非氢原子的骨架，并且共价连接有一个超大的、亲脂性的基团，包括至少9个非氢原子，并且具有至少两个阳离子大于阴离子的基团。本发明还涉及涉及这样的分子的治疗方法，特别是包括肽衍生物和肽类似物的肽。
• Antitumoural therapies
  申请人：Lytix Biopharma AS

  公开号：EP2338522A1

  公开（公告）日：2011-06-29

  The invention relates to a peptide consisting of 2-4 amino acids comprising at least three lipophilic groups of at least 5 non-hydrogen atoms wherein one of the molecule's lipophilic groups incorporates 6 or more non-hydrogen atoms and a second lipophilic group incorporates 10 or more non-hydrogen atoms and wherein at least one lipophilic group incorporates a closed ring of at least 6 non-hydrogen atoms, said peptide having at least one more cationic than anionic moiety, and wherein at least one of the amino acids has a cationic side chain (R group) and at least one of the lipophilic groups is an amino acid side chain (R group), for use as an antitumoural agent and to a peptide consisting of 2-4 amino acids comprising a lipophilic group comprising at least 13 non-hydrogen atoms and one or more closed rings of 4 or more non-hydrogen atoms, wherein at least one of the amino acids has a cationic side chain (R group) and at least one of the amino acid side chains (R groups) is a lipophilic group of at least 4 non-hydrogen atoms, said peptide having at least two more cationic than anionic moieties, also for use as an antitumoural agent.

  本发明涉及一种由 2-4 个氨基酸组成的多肽，这些氨基酸至少包含三个亲脂基团，其中一个分子的亲脂基团包含 6 个或更多的非氢原子，第二个亲脂基团包含 10 个或更多的非氢原子，并且至少有一个亲脂基团包含至少 6 个非氢原子的闭环、所述肽具有至少一个阳离子多于阴离子的分子，其中至少一个氨基酸具有阳离子侧链（R 基团），至少一个亲脂基团是氨基酸侧链（R 基团）、用于抗肿瘤剂的肽，由 2-4 个氨基酸组成，其中亲脂基团包括至少 13 个非氢原子和一个或多个由 4 个或更多非氢原子组成的闭环、其中至少有一个氨基酸具有阳离子侧链（R 基团），至少有一个氨基酸侧链（R 基团）是由至少 4 个非氢原子组成的亲脂基团，所述肽具有至少两个阳离子多于阴离子的分子，也可用作抗肿瘤剂。